

33rd Annual Cancer Progress Conference, May 10th – 12th 2022

DAY ONE: MAY 10, 2022

9:45 – 10:00 am

Opening Remarks

Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting

10:00 – 11:00 am

Patients Front and Center

Moderator: T.J. Sharpe, melanoma survivor, Patient Engagement Program Manager, Medidata Solutions

Panelists:

- David Downs, DLBCL survivor, patient advocate
- Ceinwen Giles, Founding Director, Shine Cancer Support, and Chair, NHS Cancer Programme Patient and Public Voices Forum
- Brian Leyland Jones, MB BS, PhD, CMO, National Foundation for Cancer Research
- Karen Peterson, TNBC survivor, Founder, Karen's Club
- LaShell Robinson, Director, Diversity and Inclusion in Clinical Trials, Takeda

11:00 am – 12:00 pm

How to Catch and Treat Cancer Early

Moderator: Brian Leyland Jones, MB BS, PhD, CMO, National Foundation for Cancer Research

Panelists:

- Peter Bach, MD, CMO, Delfi Diagnostics
- Kapil Dhingra, MB, BS, Managing Member, KAPital Consulting LLC
- Christoph Lengauer, PhD, MBA, Partner, Third Rock Ventures; Thrive/Exact Sciences
- John Sninsky, UCSF Clinical & Translational Science Institute, Catalyst Advisor, Diagnostics, CSO, CareDx

12:00 – 1:00 pm

Keynote Lunch Address: "Cancer Vaccination: where it fits and what is holding us back"?

Speaker: Lisa H. Butterfield, PhD, Vice President, R&D; Adjunct Professor, Parker Institute for Cancer Immunotherapy/UCSF

1:00 – 2:15 pm

State of the Art in Immuno-Oncology: Beyond PDx Inhibitors – or Not So Much

Moderator: Jeffrey M. Bockman, PhD, EVP, Oncology Practice Head, Cello Health BioConsulting

Panelists:

- Jennifer Buell, PhD, President & CEO, MiNK Therapeutics
- Michael A Curran, PhD, Associate Professor, Dept. of Immunology
- Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics
- Björn Frendeus, PhD, CSO, BioInvent
- Andrew Pierce, PhD, VP of Translational Biology, Crescendo Biologics Ltd
- Peter Sandor, MD, MBA, SVP, Primary Focus Lead Immuno-oncology, Astellas
- Emmett Schmidt, MD, PhD, VP, Clinical Oncology, Lead, External Collaborations Oncology Early Development, Merck and Co
- Dmitriy Zamarin, MD, PhD, Translational Research Director, Gynecologic Medical Oncology, Memorial Sloan Kettering Cancer Center
- Mai-Britt Zocca, PhD, CEO, IO Biotech

2:15 – 3:15 pm

The Latest Potential “Paradigm-Shifters”

Moderator: Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting

Panelists:

- Jacob Becraft, PhD, CEO, Strand Therapeutics Inc.
- Leonard A. Farber, MD, Chief Clinical and Medical Affairs Officer, Nanobiotix
- Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics
- Dora Mitchell, PhD, Vice President, Operations, Interius Biotherapeutics
- Peter Smith, PhD, CEO, MyriO Therapeutics
- Dave Altreuter, PhD, CTO, hC Bioscience
- Nicholas A. Boyle, PhD, CEO, Abintus Bio, Inc,

3:15 – 4:15 pm

ADC “The Next Generation”

Moderator: Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, Cello Health BioConsulting

Panelists:

- Giles Gallant, MD, BPharm PhD FOPQ, Senior VP, Global Head, Oncology Development, Daiichi-Sankyo
- Seema Katak, Ph.D., Senior Vice President, Biotherapeutics, Exelixis
- Hans-Georg Lerchen, PhD, CSO, Vincerx
- Timothy Lowinger, PhD, CSO, Mersana Therapeutics
- Bilal Piperdi, VP of Clinical Development, Gilead Sciences, Inc.

4:15 -5:15 pm Biotech Corporate Strategy: Inflecting Value - Partnering Versus Go It Alone

Moderator: Beth Fordham-Meier, VP, BD, Cello Health BioConsulting

Panelists:

- PJ Haley, EVP, Commercial, Exelixis
- Bruce Seeley, BA, COO, CTI Biopharma
- Göran Forsberg, PhD, CEO, Cantargia

Day 1 Cancer Progress 2022 Conference Concludes

DAY TWO: MAY 11, 2022

8:30 – 8:45 am Opening Remarks: Review of Day 1

8:45 – 9:30 am Keynote:

Speaker:

9:30 – 10:30 am When Advances in Biology Crash the Business Model: Moving the Discussion Beyond the Price of Cancer Drugs

Moderator: Ed Saltzman, Executive Chairman, Cello Heath BioConsulting

Panelists:

- Llew Keltner, MD, PhD, CEO, Epistat
- Dawn Lee, CSO, BresMed
- Roger Longman, Founder & Chairman, Real Endpoints

10:30 am – 11:30 am What's Hot/What's Not for Startups in the Quasi-Post-Pandemic Oncology World?

Moderator: Mark Simon, Partner and Co-Founder, Torrey

Panelists:

- Kapil Dhingra, MB, BS, Managing Member, KAPital Consulting LLC
- Joel Drewry, PhD, Principal, Versant Ventures
- Michael G. King Jr., Managing Director, H. C. Wainwright & Co., LLC
- Anna Turetsky, PhD, Principal, Venture Investments, The Mark Foundation for Cancer Research

11:30 am – 12:30 pm Biotech versus Pharma Perspectives – Clinical Development Strategy

Moderator:

Panelists:

- Vicki Goodman, MD, EVP, Product Development and Medical Affairs and CMO, Exelixis – to be confirmed
- Andres McAllister, PhD, CMO, BioInvent
- Lini Pandite, MD, CMO, Shattuck Labs
- Mike Rothenberg, MD, PhD, Head, Early Oncology Clinical Development, & Oncology R&D, Pfizer
- Peter Sandor, MD, SVP, Primary Focus Lead Immuno-oncology, Astellas

12:30 – 1:30 pm Break for Lunch

1:30 – 2:30pm Cancer Vaccines Redux: mRNA, Oncolytic Viruses, Or Good Old-Fashioned Peptides – Is It the Target(s), Immunization Platform, Clin Dev Strategy, or All of the Above?

Moderator: Jeffrey M. Bockman, PhD, EVP, Head of Oncology Practice, and Serom Lee, PhD, Senior Consultant, Cello Health BioConsulting

Panelists:

- Jens Bjorheim ,MD, MBA, CMO, Ultimovacs AB
- Richard Gaynor, MD, President, Research & Development, BioNTech US
- Igor Matushansky, PhD, MD,CMO & Global Head, R&D, Hookipa Pharma, Inc.
- Christophe Queva, PhD, CSO, Oncorus Inc.
- Erik Digman Wiklund, PhD, M.Sc, CEO , Targovax
- Lauren Wood, MD, PhD, CMO, PDS Biotechnology Corporation

2:30 – 3:30pm Does RNA Rule the World?

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists:

- Jacob Becraft, PhD, CEO, Co-founder, Strand Therapeutics
- Dietrich A. Stephan, Ph.D, Chairman and CEO, NeuBase Therapeutics
- Maria Luisa Pineda, PhD, Chief Executive Officer and Co-Founder, Envisagenics, Inc.
- Leslie Williams, Co-Founder, President & CEO, hC Bioscience, Inc.

3:30 – 4:30 pm

Degraders & Beyond: The Rise of Diverse Heterobifunctional Molecules

Moderator: Jeremy Goldberg, Operating Partner, Arsenal Capital Partners

Panelists:

- Adam Crystal, MD, PhD, CMO, C4 Therapeutics
- Eric Fischer, PhD, Center for Protein Degradation, Dana-Farber Cancer Institute
- Dan Grau, CEO, Avilar Therapeutics
- Peter Park, CSO, Orum Therapeutics
- Mark Rolfe, Ph.D., SVP, R&D, Oncogenesis Thematic Research Center, Bristol Myers Squibb
- Anil Vasudevan, PhD, Senior Director, Abbvie
- Michael Visser, Senior Investigator II, Novartis Institutes for BioMedical Research

Day 2 Cancer Progress 2022 Conference Concludes

DAY THREE: MAY 12, 2022

9:00 – 9:15 am

Opening Remarks: Review of Day 2

9:15 – 10:00 am

Keynote Address: "Overcoming barriers to CAR-T cell therapy for solid tumors"

Speaker: Shivani Srivastava PhD, Assistant Professor
Human Biology Division, Fred Hutchinson Cancer Research Center

10:00 – 11:00 am

Growing Pains – Navigating the Precipitous Path Towards Commercialization

Moderator:

Panelists

- Andrew Allen, MD, PhD, President & CEO, Gritstone Bio
- Sunil Joshi, Head, MS MBA, Oncology Cell Therapy, Bayer Healthcare Pharmaceuticals
- Steven J Klein, PhD, MBA, CBO, Epiteopea
- Michael DeRidder, PhD, VP, Medicine Commercialization Leader, Oncology Cell Therapy, GlaxoSmithKline plc
- Peter Sandor, MD, SVP, Primary Focus Lead Immuno-oncology, Astellas
- Rodney Varner, Executive Chairman and CEO, Genprex Inc.

11:00 am – 12:00 pm Tortoises and Hares – De-risking Strategies Towards Multiplexed Candidates

Moderator:

Panelists:

- Gregory Block, PhD, Senior Vice President, Corporate Development, Notch Therapeutics
- Eliot Bourk, PhD, VP, Head of Business & Corporate Development, Chimeric Therapeutics
- David C. White, PhD, CEO, Modulari-T Biosciences
- Paul D. Rennert, President & CSO, Aleta Biotherapeutics
- Bob Valamehr, PhD, Chief R&D Officer, Fate Therapeutics
- Tom Wilton, CBO, Carisma Therapeutics Inc.

12:00 – 1:00 pm Break for Lunch

1:00 – 2:00 pm Selling the Cell – Cost-benefit Considerations for Complex Therapeutics

Moderator:

Panelist:

- Frank Borriello, MD, PhD, Scientific Founder & CEO, Alloplex Biotherapeutics Inc.
- Gregory Fiore, MD, CEO, Exacis Biotherapeutics
- Daniel Gladwell, Chief Strategy Officer, BresMed
- Maurits Geerlings, MD, MBA, CEO, NanoCell Therapeutics, Inc.
- Sabrina Kuttruff-Coqui, PhD, VP Business Planning & Portfolio Strategy, Immatics
- Jason Litten MD, Chief Medical Officer, Artiva Biotherapeutics
- Peretz Partensky, PhD, CEO, ImmuneBridge
- Ramon Tiu, MD PhD, Cell Therapy Lead, Takeda
- Satish Valluri, Janssen

2:00 – 3:00 pm Building on Success – Clinical and Commercial Dynamics in Heme Malignancies and Hematopoietic Transplantation

Moderator:

Panelists:

- Robert Ang, MBBS, MBA, CEO, Vor Bio
- NexImmune TBD
- Francesco Galimi, MD, PhD, Senior VP, CMO, Adicet Bio
- Lore Gruenbaum, PhD, VP of Therapy Acceleration Program, Leukemia & Lymphoma Society
- Mythili Koneru, MD, PhD, CMO, Marker Therapeutics Inc.
- Charles Nicolette, PhD, President & CEO, CoIMMUNE Inc.

3:00 – 4:00 pm

Tools of the Trade – Strategic Positioning of Emerging Cell Types, Target Discovery Engines, and Gene Engineering Tools

Moderator: Michael C. Rice, MS, MBA, VP, Head of Advanced Therapeutics, Cello Health BioConsulting

Panelists:

- Cory Bentley, Ph.D. ,R&D, Abintus Bio, Inc.
- Richard Boyd, PhD, CSO, Cartherics
- William Ho, Director, President, CEO, and Co-Founder, In8bio
- Reagan Jarvis, CEO and Scientific Founder, Anocca
- Lynnet Koh, CEO & Founder, Targazyme, Inc.
- Dora Mitchell, PhD, Vice President, Operations, Interius Biotherapeutics

4:00 – 5:00 pm

Battle of the Modalities: The Sequel to the Sequel – Revenge of the Nerds

Panelists:

- Jeff Bockman, PhD, EVP, Oncology Practice Head
- Viraj Parekh, PhD, Sr Consultant, Oncology Lead
- Mike Rice, MS, MBA, VP, Head of Advanced Therapeutics
- Joel Sandler, PhD, Principal, Cancer Cell Therapy Practice Lead

Cancer Progress 2022 Conference Concludes